In short
This article discusses the ongoing clinical trials of GSK3965193B, a promising drug being studied for the treatment of chronic hepatitis B infection. The trials aim to assess the safety, tolerability, and effectiveness of GSK3965193B when used alone and in combination with another drug called bepirovirsen. These studies involve both healthy participants and those living with chronic hepatitis B, focusing on how the drug affects the body and its potential to combat the hepatitis B virus.
At a glance
- Drug Name
- GSK3965193B
- Condition Studied
- Chronic Hepatitis B
- Study Design
- Randomized, Double-blind, Multi-center, Placebo-controlled
- Study Parts
- Part 3: Monotherapy followed by optional bepirovirsen; Part 4: Combination therapy with bepirovirsen
- Primary Objectives
- 1. Assess safety and tolerability; 2. Evaluate pharmacodynamic effects; 3. Determine efficacy in combination with bepirovirsen
- Key Inclusion Criteria
- 1. Age 18-65; 2. Chronic HBV infection ≥6 months; 3. Stable NA therapy; 4. HBsAg >100 IU/mL; 5. HBV DNA <90 IU/mL
- Key Exclusion Criteria
- 1. Significant health issues; 2. Liver cirrhosis; 3. Recent immunosuppressive treatment; 4. Co-infection with HCV, HIV, or HDV
- Primary Endpoints
- 1. Adverse events incidence; 2. HBsAg reduction (Part 3); 3. Complete response rate (Part 4)
What is GSK3965193B?
GSK3965193B is an investigational drug being developed by GlaxoSmithKline for the treatment of chronic hepatitis B (CHB). It is currently undergoing clinical trials to assess its safety, effectiveness, and how it interacts with the body.
What condition does GSK3965193B target?
GSK3965193B is specifically designed to treat chronic hepatitis B. Chronic hepatitis B is a long-lasting liver infection caused by the hepatitis B virus (HBV). This condition can lead to serious liver problems, including cirrhosis and liver cancer, if left untreated.
How does GSK3965193B work?
While the exact mechanism of action is not detailed in the provided information, GSK3965193B is being studied for its ability to affect the levels of hepatitis B surface antigen (HBsAg) in the blood. HBsAg is a protein found on the surface of the hepatitis B virus and is used as a marker for active infection.
Current research on GSK3965193B
GSK3965193B is being studied in a multi-part clinical trial:
- Part 3: This part of the study examines GSK3965193B as a monotherapy (used alone) in patients with chronic hepatitis B who are already on stable nucleos(t)ide analog (NA) therapy. It involves 28 days of treatment followed by a two-week observation period.
- Part 4: This part investigates the combination of GSK3965193B with another drug called Bepirovirsen in patients with chronic hepatitis B who are on stable NA therapy.
How is GSK3965193B administered?
GSK3965193B is administered orally in the form of a tablet. In the current trials, it is given daily for 28 days.
Combination therapy with Bepirovirsen
One of the key aspects of the research is studying GSK3965193B in combination with another drug called Bepirovirsen. This combination therapy is being investigated to see if it can provide better results than either drug alone. The main goal is to achieve a complete response, which is defined as undetectable levels of both HBV DNA and HBsAg in the blood for 6 consecutive months after the planned end of treatment.
Who is eligible for GSK3965193B trials?
The trials have specific eligibility criteria. Some key points include:
- Participants must be between 18 and 65 years old
- They must have documented chronic HBV infection for at least 6 months
- Participants should be on stable nucleos(t)ide analog therapy
- They must have specific levels of HBsAg and HBV DNA in their blood
- Certain medical conditions, such as liver cirrhosis, hepatocellular carcinoma, or co-infection with other viruses like HIV or hepatitis C, would exclude a person from participating
Safety monitoring during trials
During the trials, participants are closely monitored for safety. This includes:
- Tracking the occurrence of adverse events (side effects)
- Regular blood tests to check liver function and other health markers
- Monitoring of vital signs and heart function
- Tests to check for any effects on nerve function
It's important to note that GSK3965193B is still in the experimental stage. While it shows promise, more research is needed to fully understand its effectiveness and safety profile in treating chronic hepatitis B.